Premium
Neomycin inhibits inositol phosphate formation in human platelets stimulated by thrombin but not other agonists
Author(s) -
Siess Wolfgang,
Lapetina Eduardo G.
Publication year - 1986
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/0014-5793(86)80011-4
Subject(s) - neomycin , platelet , inositol , chemistry , phospholipase c , thrombin , inositol phosphate , secretion , biochemistry , phospholipid , medicine , enzyme , receptor , membrane , antibiotics
Neomycin (0.1–1 mM) added to human platelet‐rich plasma or washed platelets prelabeled with [ 3 H]inositol inhibits aggregation, ATP secretion (ID 50 0.2 mM) and formation of [ 3 H]inositol mono‐, bis‐ and trisphosphate (ID 50 0.6–0.8 mM) in response to thrombin (0.25). The production of inositol phosphates in response to other platelet agonists (vasopressin, platelet activating factor, prostaglandin endoperoxide analogs and collagen) is not inhibited by neomycin, even at a concentration of 2 mM. At this concentration neomycin reduces the secretion of ATP stimulated by these agents (by up to 50%). The results indicate that neomycin has multiple effects on platelets that are unrelated to a specific inhibition of inositol phospholipid degradation by phospholipase C. Low concentrations (0.1–1 mM) of neomycin might selectively inhibit the interaction of thrombin with the platelet surface, and high concentrations (> 2 mM) might unspecifically reduce platelet secretion in response to various platelet agonists.